论文部分内容阅读
美国食品药品管理局(The Food and Drug Administration,FDA)已批准修订葛兰素史克生物制品公司的单价口服轮状病毒减毒活疫苗(Oral Rotavirus Attenuated Live Vaccine,RV1;商品名为Rotarix)和默克生物制品公司的五价RV(RV5,商品名为Rota Teq)的产品说明书,将肠套叠病史作为RV接种的禁忌证。FDA分别在2011年2月和2011年7月批准了RV1和RV5的修订。美国疾病控制与预防中心(Centers for Disease Control and Prevention,CDC)正在更新RV1和RV5接种建议,将肠套叠病史纳为RV接种的禁忌证。之前,CDC
The Food and Drug Administration (FDA) has approved the revision of GSK’s Oral Rotavirus Attenuated Live Vaccine (RV1; trade name Rotarix) and Moore The Biotech Company’s Pentavalent RV (RV5, trade name, Rota Teq), product specification, uses the history of intussusception as a contraindication for RV vaccination. The FDA approved the amendments to RV1 and RV5 in February 2011 and July 2011, respectively. The Centers for Disease Control and Prevention (CDC) is updating RV1 and RV5 vaccination recommendations to document the history of intussusception as a contraindication for RV vaccination. Before, CDC